Refine
Year of publication
Document Type
- Preprint (41)
- Article (21)
- Conference Proceeding (4)
- Report (1)
- Working Paper (1)
Has Fulltext
- yes (68)
Is part of the Bibliography
- no (68)
Keywords
- Hadron-Hadron Scattering (2)
- Autologous stem cell transplantation (1)
- Brain tumor (1)
- Children (1)
- High-dose chemotherapy (1)
- Lenalidomide (1)
- Methionine (1)
- Molecular imaging (1)
- Multiple myeloma (1)
- PET (1)
- Relapse (1)
- Second-line treatment (1)
Institute
- Physik (65)
- Frankfurt Institute for Advanced Studies (FIAS) (52)
- Informatik (52)
- Medizin (2)
The effect of a single HOM-damper cell within a channel of undamped cells is described theoretically using an equivalent circuit model. From this a simple equation can be derived which relates the Q-value of the single damping-cell, the bandwidth of the passband under consideration, and the additional phase shift which is introduced by the damper cell to provide energy flow into the damper cell. This equation immediately shows the limitations of such single cell damping systems. Comparisons with experimental results are shown.
By replacing the irises in an electron linac by a slit one gets a structure capable of focussing/defocussing an electron beam (rf-quadrupoles). Therefore one can think of a combination of rf- and conventional magnetic quadrupoles for transversal focussing in linear-colliders. Furthermore they can meet the demands of BNS-damping without initial energy spread. Considering multibunch-operation of a collider, the long-range wake behaviour of this kind of structure has to be investigated. A three-cell structure has been built and investigated for dipole-type transversal long-range wakes. The experimental results are compared to numerical simulations done with MAFIA.
Mode propagation in an iris type accelerator section loaded with single heavily HOM-damped cells
(1994)
The wakefield effects in accelerator sections for future linear colliders will be reduced either by damping by detuning or by a combination of both. For the DESY/THD linac [1] it is forseen to employ heavily HOM-damped cells to provide a strong coupling to the TE/TM11-dipole passband as well as to the TM/TE11-dipole passband. For our experiments we have used wall-slotted damping cells. This leads to several problems concerning the propagation of fundamental and HOM-modes. Experimental investigations have been done. Results are presented.
To reach high luminosities in future linear colliders short range wakes havea to be controlled in the range of X-band frequencies or higher. Rectangular irises can be used to introduce strong focusing quadrupole-like rf-fields. Even circular irises in iris-loaded accelarator structures have the capability of focusing if the particle velocity differs from phase velocity. Theoretical investigations concerning the focusing strength to be expected are presented. Their applicability for linear colliders is discussed.
A new method for measuring quality factors in cavities is presented. This method is capable of measuring Q-factors in heavily damped as well as in undamped cavities. In addition, the possibility of separating overlapping modes and measuring their Q-factors is provided. Measurements on HOM (higher order mode) damped cavities for the DESY/THD linear collider project are presented
Die Verbreitung von Carex hordeistichos in Hessen wurde während der Jahre 1999 bis 2012 untersucht. Die Art war aus 7 Fundgebieten in der Wetterau (4), dem Main-Taunus-Vorland (1), der Hessischen Rheinebene (1) und dem Vorderen Odenwald (1) bekannt. Nur die Population in der Wetterau bei Nieder-Wöllstadt besteht noch, 2012 war sie auf 1 Pflanze reduziert. Die übrigen Vorkommen sind seit über hundert Jahren verschollen und konnten nicht bestätigt werden. Möglichkeiten, die Art in Hessen vor dem Aussterben zu bewahren, werden diskutiert. Die Naturschutzbehörde des Wetteraukreises ist seit 1997 bemüht, im Rahmen eines Artenhilfsprogramms die existente Population zu stärken und neue aufzubauen.
Background: Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have led to the approval of lenalidomide for RMM patients and lenalidomide/dexamethasone has since become a widely accepted second-line treatment. Furthermore, in RMM patients consolidation with high-dose chemotherapy plus autologous stem cell transplantation has been shown to significantly increase progression free survival (PFS) as compared to cyclophosphamide in a phase III trial. The randomized prospective ReLApsE trial is designed to evaluate PFS after lenalidomide/dexamethasone induction, high-dose chemotherapy consolidation plus autologous stem cell transplantation and lenalidomide maintenance compared with the well-established lenalidomide/dexamethasone regimen in RMM patients.
Methods/Design: ReLApsE is a randomized, open, multicenter phase III trial in a planned study population of 282 RMM patients. All patients receive three lenalidomide/dexamethasone cycles and - in absence of available stem cells from earlier harvesting - undergo peripheral blood stem cell mobilization and harvesting. Subsequently, patients in arm A continue on consecutive lenalidomide/dexamethasone cycles, patients in arm B undergo high dose chemotherapy plus autologous stem cell transplantation followed by lenalidomide maintenance until discontinuation criteria are met. Therapeutic response is evaluated after the 3rd (arm A + B) and the 5th lenalidomide/dexamethasone cycle (arm A) or 2 months after autologous stem cell transplantation (arm B) and every 3 months thereafter (arm A + B). After finishing the study treatment, patients are followed up for survival and subsequent myeloma therapies. The expected trial duration is 6.25 years from first patient in to last patient out. The primary endpoint is PFS, secondary endpoints include overall survival (OS), RR, time to best response and the influence of early versus late salvage high dose chemotherapy plus autologous stem cell transplantation on OS.
Discussion: This phase III trial is designed to evaluate whether high dose chemotherapy plus autologous stem cell transplantation and lenalidomide maintenance after lenalidomide/dexamethasone induction improves PFS compared with the well-established continued lenalidomide/dexamethasone regimen in RMM patients. Trial registration: ISRCTN16345835 (date of registration 2010-08-24).